2019 American Transplant Congress
The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen
*Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…2019 American Transplant Congress
A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
*Purpose: Beginning in December 2015, our center instituted a protocol change moving to de novo use of LCPT. The objective of this study is to…2019 American Transplant Congress
Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients
*Purpose: Recent evidence suggests that belatacept reduces the durability of pre-existing antibodies to class I and class II human leukocyte antigens (HLA). Belatacept has a…2019 American Transplant Congress
A Novel Apparatus Mimicking Hypertensive Kidney With Primary Cultured Human Kidney Cells Using Rotational Force: Application To In Vitro Drug Screening In Kidney Transplant Recipients
*Purpose: Cell culture is an essential part of the development for various medical technologies such as identifying the cause of the disease and developing new…2019 American Transplant Congress
Incidence, Risk Factors, Outcomes and Clinical Management of BK Viremia in the Modern Era of Kidney Transplantation
Toronto General Hospital, Toronto, ON, Canada
*Purpose: BK viremia is endemic among kidney transplant recipients (KTR). Previous work has not compared the incidence, risk factors, and outcomes of any vs. clinically…2019 American Transplant Congress
Immunologic Outcomes In Recipients Of Orthotopic Liver Transplant Induced Only With Steroids
The University of Texas Medical Branch, Galveston, TX
*Purpose: Liver allografts are resistant to antibody mediated rejection (AMR) in the presence of preformed alloantibodies. In most cases donor specific antibodies (DSAs) disappear a…2019 American Transplant Congress
Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation
1Johns Hopkins University, Baltimore, MD, 2University of Alabama, Birmingham, AL
*Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…2019 American Transplant Congress
Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation
*Purpose: Over 100,000 candidates await a kidney transplant on the national United Network for Organ Sharing (UNOS) waitlist. Among these candidates, one-third have pre-formed antibodies…2019 American Transplant Congress
Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy
*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the…2019 American Transplant Congress
Improving Medication Adherence and Outcomes in Adult Kidney Transplant Patients Using SystemCHANGETM: Results of the Medication Adherence Given Individual Change (MAGIC) Randomized Clinical Trial
*Purpose: Medication non-adherence is an obdurate problem associated with poor outcomes and staggering costs. Even with multi-faceted interventions, effect sizes reported in meta-analyses of medication…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 138
- Next Page »